Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, announced that it intends to offer and sell, subject to market conditions, $75 million in shares of its common stock in an underwritten public offering.
June 8, 2021
· 3 min read